



Anti-L1CAM

A Novel Efficacious Immunotherapy for the Treatment of Solid Tumors

Anne Schmidt CEO

Elthera AG

anne.schmidt@elthera.com

www.elthera.com


Phone: +41 79 771 25 35

Our Mission

We develop novel precision medicine immunotherapies to improve the lives of patients with highly aggressive cancers

Our Company

- Biotech Start-up company created 2016 in Switzerland
- Experienced founder and management team
- Developing Antibody-based therapies against **L1 cell adhesion molecule (L1CAM)**
- Start preclinical development in Q4 / 2020
- Looking for Series A financing and / or partners



L1 cell adhesion molecule (L1CAM)

- Overexpressed in many different cancer types
- Expression correlated with poor prognosis
- Multiple functions in cancer progression
- Expressed on cancer stem cells
- Not expressed in most healthy tissues


Two therapeutic approaches

based on novel humanized, optimized anti-L1CAM antibody


Bispecific T cell engaging antibody

Binding to L1CAM
on cancer cells

Binding to CD3
on T cells



Crosslinking of tumor cells to cytotoxic T cells leads to polyclonal activation of T cells and potent killing of tumor cells




Novel humanized, optimized anti-L1CAM antibody

- Very high affinity for L1CAM
- Excellent biophysical properties
- Binding to functionally relevant epitope on L1CAM

Antibody-drug conjugate (ADC)

Binding to L1CAM
on cancer cells




L1CAM-mediated internalization of antibody drug-conjugate leads to delivery of cytotoxic drug and killing of tumor cells

Potent anti-tumor effects


observed for both therapeutic approaches

Bispecific T cell engaging antibody



Extremely potent T cell mediated killing of L1CAM-expressing tumor cells

Antibody-drug conjugate (ADC)



Efficient and potent killing of L1CAM-expressing tumor cells by anti-L1CAM amanitin conjugate

Market Opportunity

First-in-class therapy with Blockbuster potential




Predicted sales of > € 1 Billion for initial indications pancreatic and ovarian cancer

High potential for

- Expansion to additional L1CAM-positive indications such as colorectal, lung, breast cancer, melanoma, and others
- Combination with checkpoint inhibitors, chemotherapy, anti-angiogenic therapies


Ovarian cancer




€ 0.43 B
Annual sales

Pancreatic cancer

€ 1.0 B
Annual sales



Investment rational



Looking for Series A funding and/or partner for the development of anti-L1CAM x CD3 bispecific antibody

Looking for experienced partner for the anti-L1CAM drug conjugate development



Please contact:

Elthera AG

anne.schmidt@elthera.com

www.elthera.com

Phone: +41 79 771 25 35